Election action may be winding down in India, at least for now, but keep an eye on deal street, with at least two domestic firms that feature in the top 50 speculated to be on the block and a small life sciences solutions provider apparently open to a buyout. That’s in addition to on-and-off stake sale rumours pertaining to Cipla Limited.(Also see "'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action" - Scrip, 17 May, 2024.)
Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?
Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.
More from Business
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.